Market Data
Market Cap₹858.84 Cr.
52W High₹363.05
Current Price₹363.05
52W Low₹95
Face Value₹10
Performance
EPS (TTM)₹-0.25
EPS Prev Qtr₹-0.9
EBITDA Qtr₹-1.1 Cr.
Book Value₹-2
Financial Health
Debt/Equity-0.71
Total Assets₹71.313 Cr.
Promoter Holding75 %
Valuation
Industry P/E33.81
Price to Book-202.5
Key Metrics
Face Value
₹10
About Bafna Pharmaceuticals Ltd
Healthcare · Pharmaceuticals
Bafna Pharmaceuticals Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹858.84 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a significant promoter holding of 75%, indicating strong control and alignment of interests.
Weaknesses
- The P/B ratio is negative at -176.65, suggesting severe financial distress or accounting anomalies.
- The Debt to Equity ratio is negative at -0.71, indicating potential severe financial irregularities or negative equity.
- Key performance metrics such as Revenue, Net Profit, ROCE, and ROE are not available, making it impossible to assess operational efficiency and profitability.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2018 | Jun 2019 | Sep 2019 | |
|---|---|---|---|
| Sales | 8.84 | 6.85 | 11.57 |
| ↳ QoQ Growth | - | -22.5% | +68.9% |
| Expenses | 9.41 | 10.73 | 12.66 |
| Operating Profit | -0.57 | -3.88 | -1.1 |
| OPM % | -6.45% | -56.64% | -9.51% |
| Other Income | -0.03 | 0.3 | 0.59 |
| Interest | 0.62 | 0.13 | 0.04 |
| Depreciation | 0.75 | 1.02 | 0.72 |
| EBITDA | 0.18 | -2.86 | -0.38 |
| EBITDA Margin % | 2.04% | -41.75% | -3.28% |
| Profit Before Tax | -1.22 | -3.71 | -0.55 |
| Tax % | -4.1% | 42.59% | -7.27% |
| Net Profit | -1.28 | -2.13 | -0.59 |
| ↳ QoQ Growth | - | -66.4% | +72.3% |
| EPS | -0.8 | -0.9 | -0.25 |
Balance Sheet
| Mar 2019 | Mar 2020 | |
|---|---|---|
| Equity Capital | 23.66 | 2.3656 |
| Reserves | -4.6 | -6.6067 |
| Borrowings | 46.23 | 3.02 |
| Other Liabilities | 6.6 | 72.53 |
| Total Liabilities | 71.89 | 71.3126 |
| Fixed Assets | 37.02 | 35.0049 |
| CWIP | - | 0.212 |
| Investments | 0 | 0 |
| Other Assets | 34.87 | 36.1 |
| Total Assets | 71.89 | 71.3126 |
Cash Flows
| Mar 2020 | |
|---|---|
| Cash from Operating Activity | -34.3087 |
| Cash from Investing Activity | 32.7748 |
| Cash from Financing Activity | 7.3014 |
| Net Cash Flow | 5.7675 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 75% | 75% | 75% | 75% |
| FIIs % | 9.34% | 9.34% | 9.34% | 9.34% |
| DIIs % | 0% | 0% | 0% | 0% |
| Public % | 12.03% | 12.13% | 12.13% | 11.97% |
| No. of Shareholders | 7,572 | 7,119 | 6,928 | 7,062 |
Major Shareholders (>1%)
- Srjr Lifesciences LlpPromoter and Promoter Group74.57%
- M7 Global Fund Pcc-aerionPublic Shareholding3.21%
- M7 Global Fund Pcc - Cell Dewcap FundPublic Shareholding3.12%
- Zeal Global Opportunities FundPublic Shareholding3.01%
As of 2026-06-30View all shareholders →